These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7648837)

  • 21. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
    Jamjian C; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.
    Johnson AP; Warner M; Hallas G; Livermore DM
    J Antimicrob Chemother; 2000 Jul; 46(1):125-8. PubMed ID: 10882701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.
    Lozniewski A; Lion C; Mory F; Weber M
    Pathol Biol (Paris); 2000 Jun; 48(5):463-6. PubMed ID: 10949841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
    Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
    Ristow TA; Noskin GA; Warren JR; Peterson LR
    Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
    Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
    Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.
    Pankuch GA; Lichtenberger C; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1653-6. PubMed ID: 8807057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
    Lorian V; Fernandes F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():63-6. PubMed ID: 9511065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae.
    Fremaux A; Sissia G; Cohen R; Geslin P
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():19-23. PubMed ID: 1399946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.
    Biedenbach D; Wanger A; Jones RN
    J Antimicrob Chemother; 1996 Sep; 38(3):553-5. PubMed ID: 8889731
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
    Tenover FC; Baker CN
    J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.